Idorsia (IDIA) Q3 2026 earnings summary

Executive summary

• 9M 2026 US GAAP revenue was CHF 172m vs CHF 173m YoY; net loss widened to CHF 206m from CHF 34m, including a CHF 47m debt-extinguishment loss.

• QUVIVIQ sales reached CHF 142m, up 54% YoY; FY guidance was reaffirmed, with US GAAP operating-loss guidance improved.

Financial highlights

• 9M non-GAAP revenue was CHF 166m vs CHF 167m; US GAAP operating loss was CHF 99m vs income of CHF 23m, and non-GAAP operating loss was CHF 85m vs CHF 53m.

• 9M US GAAP net loss was CHF 206m vs CHF 34m; non-GAAP net loss was CHF 123m vs CHF 65m.

• Q3 US GAAP revenue was CHF 62m vs CHF 41m; US GAAP net loss was CHF 53m vs CHF 86m.

• US GAAP operating expenses were CHF 272m, CHF 20m higher YoY excluding a CHF 90m prior-year one-off gain.

Segment performance

• QUVIVIQ 9M sales were CHF 142m vs CHF 92m, across North America and Europe; partner sales were CHF 12m, mainly in Asia-Pacific.

• 9M contract revenue included CHF 3m in royalties, CHF 4m in milestones and CHF 7m in other revenue, primarily an EMS Latin America exclusivity fee of USD 8m.

• Growth drivers included accelerating demand, wider geographic reach, broader access and increasing primary-care penetration.